BACKGROUND: This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: A standard 3+3 study design was used. Patients were sequentially enrolled to be treated with IMO-2055 (0.16, 0.32, or 0.48 mg/kg/day; days 1, 8, 15), 5-fluorouracil (1,000 mg/m(2)/day; days 1-4), cisplatin (100 mg/m(2)/day; day 1) and cetuximab (400 mg/m(2)/day first dose; then 250 mg/m(2)/day; days 1, 8, 15) every 3 weeks. RESULTS: Thirteen patients received IMO-2055. Dose-limiting toxicities (DLTs; ie, any Grade [G]3/4 treatment-related adverse events [TEAEs] in cycle 1) occurred in 2/4 patients treated with IMO-2055 0.32 mg/kg (G4 hypokalemia and hypomagnesemia [n=1]; G4 septicemia, hyperthermia, febrile neutropenia, and G3 hypotension [n=1]). In the IMO-2055 0.16-mg/kg expansion cohort, 1 patient experienced DLTs of G3 sepsis, bacteremia, and hyperthermia. The most common G ≥ 3 TEAEs were neutropenia (n=9; not including febrile neutropenia [n=1]), hypokalemia (n=5), and hypomagnesemia (n=4). Serious adverse events (SAEs) occurred in 8 patients, including 4 with SAEs considered IMO-2055 related; 1 of these patients died. Best response achieved overall was partial response in 3 patients and stable disease in 9 patients. The overall safety profile led to early trial termination; the safety monitoring committee did not confirm the MTD (formally IMO-2055 0.16 mg/kg). CONCLUSIONS: Regimens combining IMO-2055 and PFE cannot be recommended for further development in R/M SCCHN patients.
BACKGROUND: This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). METHODS: A standard 3+3 study design was used. Patients were sequentially enrolled to be treated with IMO-2055 (0.16, 0.32, or 0.48 mg/kg/day; days 1, 8, 15), 5-fluorouracil (1,000 mg/m(2)/day; days 1-4), cisplatin (100 mg/m(2)/day; day 1) and cetuximab (400 mg/m(2)/day first dose; then 250 mg/m(2)/day; days 1, 8, 15) every 3 weeks. RESULTS: Thirteen patients received IMO-2055. Dose-limiting toxicities (DLTs; ie, any Grade [G]3/4 treatment-related adverse events [TEAEs] in cycle 1) occurred in 2/4 patients treated with IMO-2055 0.32 mg/kg (G4 hypokalemia and hypomagnesemia [n=1]; G4 septicemia, hyperthermia, febrile neutropenia, and G3 hypotension [n=1]). In the IMO-2055 0.16-mg/kg expansion cohort, 1 patient experienced DLTs of G3 sepsis, bacteremia, and hyperthermia. The most common G ≥ 3 TEAEs were neutropenia (n=9; not including febrile neutropenia [n=1]), hypokalemia (n=5), and hypomagnesemia (n=4). Serious adverse events (SAEs) occurred in 8 patients, including 4 with SAEs considered IMO-2055 related; 1 of these patients died. Best response achieved overall was partial response in 3 patients and stable disease in 9 patients. The overall safety profile led to early trial termination; the safety monitoring committee did not confirm the MTD (formally IMO-2055 0.16 mg/kg). CONCLUSIONS: Regimens combining IMO-2055 and PFE cannot be recommended for further development in R/M SCCHN patients.
Authors: Penélope D Sánchez-González; Francisco J López-Hernández; José M López-Novoa; Ana I Morales Journal: Crit Rev Toxicol Date: 2011-08-12 Impact factor: 5.635
Authors: Michael K Gibson; Yi Li; Barbara Murphy; Maha H A Hussain; Ronald C DeConti; John Ensley; Arlene A Forastiere Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Vincenzo Damiano; Rosa Caputo; Roberto Bianco; Francesco P D'Armiento; Antonio Leonardi; Sabino De Placido; A Raffaele Bianco; Sudhir Agrawal; Fortunato Ciardiello; Giampaolo Tortora Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: C Manegold; N van Zandwijk; A Szczesna; P Zatloukal; J S K Au; M Blasinska-Morawiec; P Serwatowski; M Krzakowski; J Jassem; E H Tan; R J Benner; A Ingrosso; S J Meech; D Readett; N Thatcher Journal: Ann Oncol Date: 2011-04-04 Impact factor: 32.976
Authors: John A Thompson; Timothy Kuzel; Beverly J Drucker; Walter J Urba; Ronald M Bukowski Journal: Clin Genitourin Cancer Date: 2009-10 Impact factor: 2.872
Authors: J B Vermorken; J Guigay; R Mesia; J M Trigo; U Keilholz; A Kerber; U Bethe; M Picard; T H Brummendorf Journal: Br J Cancer Date: 2011-05-03 Impact factor: 7.640
Authors: A Ruzsa; M Sen; M Evans; L W Lee; K Hideghety; S Rottey; P Klimak; P Holeckova; J Fayette; T Csoszi; J Erfan; U Forssmann; T Goddemeier; A Bexon; C Nutting Journal: Invest New Drugs Date: 2014-06-04 Impact factor: 3.850